One of the biomarkers we have highlighted, CRP, has previously been proposed as an agent allowing monitoring of chronic inflammation (reviewed Volanakis, 2001) and also been studied as a possible biomarker of lung cancer risk (Chaturvedi et al., 2010, Van Hemelrijck et al., 2011). Here, CRP is linked to lung cancer.